TW200418496A - A composition for repairing injured skin - Google Patents
A composition for repairing injured skin Download PDFInfo
- Publication number
- TW200418496A TW200418496A TW092131556A TW92131556A TW200418496A TW 200418496 A TW200418496 A TW 200418496A TW 092131556 A TW092131556 A TW 092131556A TW 92131556 A TW92131556 A TW 92131556A TW 200418496 A TW200418496 A TW 200418496A
- Authority
- TW
- Taiwan
- Prior art keywords
- weight
- composition
- present
- iodine
- skin damage
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000000346 sugar Nutrition 0.000 claims description 25
- 230000037380 skin damage Effects 0.000 claims description 16
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 4
- 229940042880 natural phospholipid Drugs 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 3
- 231100000444 skin lesion Toxicity 0.000 claims 1
- 206010040882 skin lesion Diseases 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 24
- 150000001720 carbohydrates Chemical class 0.000 abstract description 4
- 206010063560 Excessive granulation tissue Diseases 0.000 abstract description 3
- 210000001126 granulation tissue Anatomy 0.000 abstract description 3
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 abstract 2
- 229920000153 Povidone-iodine Polymers 0.000 abstract 2
- 229960001621 povidone-iodine Drugs 0.000 abstract 2
- 230000003902 lesion Effects 0.000 abstract 1
- 230000036962 time dependent Effects 0.000 abstract 1
- -1 polyethylene Polymers 0.000 description 22
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 14
- UXYRZJKIQKRJCF-TZPFWLJSSA-N mesterolone Chemical compound C1C[C@@H]2[C@@]3(C)[C@@H](C)CC(=O)C[C@@H]3CC[C@H]2[C@@H]2CC[C@H](O)[C@]21C UXYRZJKIQKRJCF-TZPFWLJSSA-N 0.000 description 14
- 239000002674 ointment Substances 0.000 description 14
- 150000008163 sugars Chemical class 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 11
- 239000011630 iodine Substances 0.000 description 11
- 229910052740 iodine Inorganic materials 0.000 description 11
- 229920001451 polypropylene glycol Polymers 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 10
- 239000000825 pharmaceutical preparation Substances 0.000 description 9
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 150000002009 diols Chemical class 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 229920000742 Cotton Polymers 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 229960003511 macrogol Drugs 0.000 description 5
- 238000013019 agitation Methods 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229950004354 phosphorylcholine Drugs 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 239000004373 Pullulan Substances 0.000 description 2
- 229920001218 Pullulan Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 235000019423 pullulan Nutrition 0.000 description 2
- 229940083466 soybean lecithin Drugs 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 244000208874 Althaea officinalis Species 0.000 description 1
- 235000006576 Althaea officinalis Nutrition 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 108010022355 Fibroins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- WBNLUNPHVDEWFZ-UHFFFAOYSA-N P(=O)(O)(O)O.P(=O)(O)(O)OCCN Chemical compound P(=O)(O)(O)O.P(=O)(O)(O)OCCN WBNLUNPHVDEWFZ-UHFFFAOYSA-N 0.000 description 1
- FWSMOHRVWAHCHW-UHFFFAOYSA-B P(=O)([O-])([O-])[O-].[Os+4].P(=O)([O-])([O-])[O-].P(=O)([O-])([O-])[O-].P(=O)([O-])([O-])[O-].[Os+4].[Os+4] Chemical class P(=O)([O-])([O-])[O-].[Os+4].P(=O)([O-])([O-])[O-].P(=O)([O-])([O-])[O-].P(=O)([O-])([O-])[O-].[Os+4].[Os+4] FWSMOHRVWAHCHW-UHFFFAOYSA-B 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical class CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- KILNVBDSWZSGLL-UHFFFAOYSA-N colfosceril palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 239000008344 egg yolk phospholipid Substances 0.000 description 1
- 229940068998 egg yolk phospholipid Drugs 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000001035 marshmallow Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000007715 potassium iodide Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940078492 ppg-17 Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940068944 providone-iodine Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- BTQVJASSHRJHSY-UHFFFAOYSA-N trimethyl(2-phosphonooxyethyl)azanium phosphate Chemical compound [O-]P([O-])([O-])=O.C[N+](C)(C)CCOP(O)(O)=O.C[N+](C)(C)CCOP(O)(O)=O.C[N+](C)(C)CCOP(O)(O)=O BTQVJASSHRJHSY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
- A61K31/79—Polymers of vinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
200418496 玖、發明說明·· 【技術領域】 本發明係關於一種皮膚損傷修復用組合物,其係可抑制 含有醣類及普威隆蛾(聚乙烯σ比洛酮-蛾複合物、聚[(2_氧代 吼咯啶-卜基)乙烯]碘)之醫藥製劑之濃稠度隨時間升高。 【先前技術】 由於醣類,如綿白糖,具有癒合傷口及形成肉芽組織之 作用,將醣類與普威隆碘混合可用於醫藥製備物中,以療 合如褥瘡及皮膚潰瘍(例如,參照Jp_B_〇1_〇322i〇、 JP-B_06-017299 ’ Southern Medical Journal,1981,74(11), 1329-1335,及’’Byoin Yakugaku’,,1984,l〇(5),3 15_322)。 然而,由於大多數皮膚損傷修復用組合物(於下文中有時 稱為軟膏製備物)含有以糖組成之醣類及普威隆鐵,其具有 隨時間硬化之醣類固有特性。因此,當將其以塗覆於紗布 之方式用於西療照顧之領域時,其必須於搜拌及軟化已變 硬之軟膏製備物後方可使用,及於協同醫療中需經複雜之 過程與時間。 為改善此濃稠度隨時間升高之缺點,已知一種調配多種 粉末狀醣類(其平均粒子大小皆不同之)之方法 171779)、调配不具揮發性之溶劑與低碳烷胺之方法 (JP-A-11-228421)等,然而這些方法仍無法令人滿意。 粉末狀調配物亦有不易塗至損傷部位及會於空氣中飛散 而導致環境污染之缺點。 另一降低含有醣類及普威隆碘之皮膚損傷修復用組合物
〇:\89\89230.DOC -6- 200418496 /辰稠度之方法包括降低製備物中經混合或不混合之主藥聚 口物之3里,但此方法並不佳因製備物之成份會隨時間而 分離。 因此,含有醣類及普威隆碘之皮膚損傷修復用組合物, 八黏稠度及硬化不隨時間而增加之發展是必要的。 【發明内容】 本發明目標之一係提供一種皮膚損傷修復用組合物,其 y抑制含醣類及普威隆碘之醫藥製備物之黏稠度隨時間升 南〇 本發明之發明者將上述之缺點列入考量,持續多方面的 研九結果思外地發現一種具有抑制黏稠度隨時間升高及 較高穩定性之含醣類及普威隆碘之組合物,可藉由在含有 醣9威隆碘、及水之系統中調配一特定含量磷脂而獲得; 並完成本發明。 口此,本發明之一方面係為提供一皮膚損傷修復用組合 物,其含有50至90重量%之醣類、〇乃至1〇重量%之普威隆 碘ο·1至20重量%之水及〇·〇ι至ίο重量。/。之磷脂。 本备明之此含醣類及普威隆碘之皮膚損傷修復用組合 :勿,係容易使用,因其可抑制黏度隨時間升高、溫和之醫 藥製備物、及適合用在深的創口及肉芽組織表面。 本I明所使用之醣類包括如綿白糖(包括經純化綿白糖) 之非逛原糖及還原糖、葡萄糖、蜂蜜'及糖蜜,而以綿白 糖較佳。 混合之醣類含量係以醫藥製備物總重量計之50至90%,
O:\89\89230.DOC -7- 200418496 較佳為60至80%,最佳為70%。 混合之普威隆碘含量係以醫藥製備物總重量計之〇·5至 10%,較佳為1至7%,最佳為2至6°/〇。 添加之水含量係以醫藥製備物總重量計之0.1至20%,較 佳為0.3至15°/。,最佳為0.5至12%。 本發明中使用之磷脂係一含有磷酸鹽殘基,如天然磷 脂、人造磷脂、及氫化磷脂之共軛脂,其中天然形成之磷 脂係經氯化。 天然磷脂包括磷酸醯膽鹼、磷酸醯乙醇胺、磷酸醯絲胺 酸、磷酸醯肌醇、脫脂酸磷脂膽鹼、神經鞘磷脂、蛋黃卵 磷脂、大豆卵磷脂、及由如大腸桿菌之微生物粹取出之磷 脂。市售之產品有,例如,COATSOME NC_50(NOF)及 presome(Nippon Seika, Co. Ltd) ° 人造磷脂包括二油醯-磷酸醯膽鹼、二月桂醯-磷酸醯膽 鹼、二莖蔻醯-磷酸醯膽鹼、二棕櫚醯-磷酸醯膽鹼、二硬脂 醯-磷酸醯膽鹼、及棕櫚-油醯-磷酸醯膽鹼。市售之產品有, 例如,COATSOME MC-2020、COATSOME MC-4040、 COATSOME MC-6060、COATSOME MC-8080、COATSOME MC-8181、及 COATSOME MC-6081(NOF) 〇 氳化磷脂包括氫化大豆磷脂、氫化蛋黃磷脂、氫化磷酸 酉藍膽驗、及氫化鱗酸酸絲胺酸。市售之產品有Lecinol S-10,Lecinol S-10E,Lecinol S-10M,Lecinol S-10EX, Lecinol S-PIE (Nikko Chemicals,Co.)、COATSOME NC-21 (NOF)、Phospholipon及 Phosal (Aventis) 0 於這些磷脂中,以天然磷脂或氫化磷脂較佳。
O:\89\89230.DOC 200418496 於本發明中,磷脂之使用可係單獨、兩種或更多種混合, 而其混合之量係醫藥製備物之0 0丨至丨〇%重量比,較佳為 0.01至7%重量比,更佳為0.05至5%重量比,最佳為〇1至 5%。若磷脂量低於〇·〇ι%重量比即無法獲得足以穩定濃稠 度之效果。高於10%重量比之磷脂量亦不佳,因其會惡化 製備物之穩定性。 以醣類及普威隆碘之穩定性之觀點而言,本發明之皮膚 損傷修復用組合物之pH較佳為3.5至6。pH之測量係將以重 量計9份之水加至以重量計丨份之皮膚損傷修復用組合物, 加以混合,並於25°C下以pH檢測器(例如Hodba Ltd: F-24) 測量。 pH之調節可使用如鹽酸、檸檬酸、及氫氧化鈉之酸與鹼, 但醫藥製備物可做為pH緩衝系統,亦可使用乳酸緩衝劑、 擰檬酸緩衝劑、及磷酸緩衝劑。 在本發明之皮膚損傷修復用組合物中,在不妨礙本發明 之效用下,可依需要之劑量將多種其他成份加入其中,例 如其他藥物及藥理上可接受之添加物(例如增溶劑、表面活 性劑、及增稠劑)。 其他藥物包括如bFGF、EGF、HGF、及igf之成長激素, 及如絲心蛋白之蛋白質。 增溶劑包括碘化鉀、碘化鈉、甘油、聚乙二醇(macr〇g〇1) 400、聚乙二醇(macr〇g〇i) 15〇〇、聚乙二醇(macr〇g〇i) ⑼、 水乙^一醇(macrogol) 6000、聚丙一醇、丙稀醇、及雙丙稀 醇0
O:\89\89230.DOC 200418496 表面活性劑包括聚氧乙烯_(105)聚氧丙烯(5)二醇、聚氧 乙烯-(120)聚氧丙烯(40)二醇、聚氧乙烯_(16〇)聚氧丙烯(3〇) 二醇、聚氧乙烯-(196)聚氧丙稀(67)二醇、聚氧乙烯_(2〇)聚 氧丙稀(20)二醇、聚氧乙烯_(2〇〇)聚氧丙烯(7〇)二醇、聚氧 乙烯-(3)聚氧丙烯(17)二醇、聚氧乙烯气42)聚氧丙烯(67)二 醇、聚氧乙烯-(54)聚氧丙烯(39)二醇、聚氧乙烯氫化蓖麻 油、聚山梨酸脂和山梨醇酐單硬脂酸酯。 增稠劑包括普路蘭、羧甲基纖維素鈉、藻酸鈉、普威隆、 乙烯酸聚合體、甲基纖維素、瓊脂、及明膠。 本發明之皮膚損傷修復用組合物之生產可藉將本文上述 之成份混合,必要時可加熱攪拌此混合物至均勻狀態,以 製成軟膏狀態。 本發明之皮膚損傷修復用組合物較佳之使用方式,係將 其塗抹於紗布再與傷口接觸。本發明之皮膚損傷修復用組 合物,因其優良之吸水能力,具有如吸收滲出物之優良效 在此將以實例按照種類說明本發明,但本發明不限於這 些實例。 【實施方式】 實例1 軟膏製劑之製備 本發明1之產品: 將含9.5172§純水、0.0828 §氫氧化鈉、〇7§碘化鉀、〇1§ 檸檬酸、0.2 g普路蘭、1 g濃縮甘油、1 g丨,3_丁二醇、i § O:\89\89230.DOC -10- 200418496 丙二醇、70 g綿白糖、及3g普威隆碘之混合物充分混合及 捏合。之後,於此混合物中加入0.3 g氫化大豆磷脂(Lecin〇l S-10EX,Nikko Chemicals Co·)並充分捏合。再於此混合物 中加入 1 g macrogol 300、11 g 聚乙二醇(macr〇g〇i ) 4〇〇、及 加熱溶解之1.1 g聚氧乙烯(160)聚氧丙烯(3〇)_二醇,充分捏 合,並攪拌至均勻狀態以製造軟膏製備物(本發明1之產品)。 本發明2至5之產品: 表1中本發明2至4之產品係以與本發明1之產品相同之程 序製造,本發明5之產品係使用大豆卵磷脂(COATSOME NC-20,NOF)取代本發明1之產品中之氫化大豆磷脂。 比較產品1 : 將9.5172 g純水、0.0828 g氫氧化鈉、〇·7 g埃化鉀、〇. 1 g 檸檬酸、0·2 g普路蘭、1 g濃縮甘油、1 g 13-丁二醇、1 g 丙二醇、70 g綿白糖、及3 g普威隆碘之混合物充分混合及 捏合。再於此混合物中加入1 g聚乙二醇(macr〇g〇l) 3〇〇、 11_3 g聚乙二醇(macrogol) 4〇〇、及加熱溶解之丨」g聚氧乙 烯(160)聚氧丙烯(3〇)-二醇,充分捏合,並攪拌至均勻狀態 以製造軟膏製備物(比較產品丨)。 將約3 0 g此般製成之各個軟膏製備物以密封狀態及室溫 下存放於軟玻璃瓶(配有塑膠内塞及金屬蓋之Νο·4標準(JIS) 瓶)’之後評估隨時間改變之濃稠度、攪拌性、及延展性。 結果顯示於表1中。 (pH) 將1 g初製成之各個軟膏製備物與9 g之水充分混合,使用
O:\S9\89230.DOC -11 - 200418496 pH檢測益(F_24,Horiba Ltd)於25°C 下測量 pH。 (濃稠度) 於初製成時、於室溫存放3個月及12個月後測量各個軟膏 製備物之濃稠度。 使用、、口 構分析器(TA-XT2i,Stable Micro Systems Inc.), 將10 cm之小球以丨mm/s之速度針入軟膏製備物中2 之 深度’並測量針入時最大支負荷力。 (攪拌性) 於初製成時、於室溫存放3個月及12個月後測量各個軟膏 製備物之擾拌性。 授掉性之評估係依下列標準4個等級之標準,於使用木製 刮鐘攪拌軟贫製備物後,以感覺檢測。 ◎•十分容易攪拌,及非常容易使用; ◦ ··容易攪拌,及容易使用; △ •難以攪拌,但不盡然無法使用;及 X :非常難以攪拌,及無法使用。 (延展性) 於初製成時、於室渴存放3個月及12個月後測量各個軟膏 製備物之延展性。 延展性之評估係依下列標準4個等級之標準,於攪拌軟膏 製備物並以木製刮鏟塗於紗布後,以感覺檢測。 ◎•十分容易延展,及非常容易使用; ◦ ··容易延展,及容易使用; △•難以延展’但不盡然無法使用;及 X •非#難以延展,及無法使用。
O:\89\89230.DOC -12- 200418496 表1 成份 本發明之產品 比較產品 1 2 3 4 5 1 綿白糖 70 70 70 70 70 70 普威隆碘 3 3 3 3 3 3 聚乙二醇(macrogol) 300 1 1 1 1 1 1 聚乙二醇(macrogol) 400 11 10.8 8.3 6.3 11 11.3 濃縮甘油 1 1 1 1 1 1 1,3-丁二醇 1 1 1 1 1 1 丙二醇 1 1 1 1 1 1 氫化大豆磷脂 0.3 0.5 3 5 一 大豆卵碟脂 - - 一 0.3 一 聚氧化乙烯(160)聚氧 化丙烯(30)乙二醇 1.1 1.1 1.1 1.1 1.1 1.1 普路蘭 0.2 0.2 0.2 0.2 0.2 0.2 峨化鉀 0.7 0.7 0.7 0.7 0.7 0.7 檸檬酸 0.1 0.1 0.1 0.1 0.1 0.1 氫氧化鈉 0.0828 0.08 0.08 0.076 0.08 0.0828 純水 9.5172 9.52 9.52 9.524 9.52 9.5172 Ph 初製成時 4.6 4.5 4.4 4.6 4.8 4.6 濃稠度 初製成時:g 16.0 8.5 11.5 21.4 48.3 62.6 於室溫3個月 後:g 25.2 13.6 19.4 39.0 48.1 208.9 於室溫12個 30.3 14.9 21.9 32.2 45.3 254.9 攪拌性 初製成時 ◎ ◎ ◎ ◎ ◎ ◎ 於室溫3個月 後 ◎ ◎ ◎ ◎ ◎ X 於室溫12個 月後 ◎ ◎ ◎ ◎ ◎ X 延展性 初製成時 ◎ ◎ ◎ ◎ ◎ ◎ 於室溫3個月 後 ◎ ◎ ◎ ◎ ◎ 〇 於室溫12個 月後 ◎ ◎ ◎ ◎ ◎ Δ O:\89\89230.DOC -13- 200418496 含有綿白糖、普威隆碘、及水、但不含磷脂之軟膏製備 物(比較產品1),於室溫存放3個月後,明顯有濃稠度升高及 攪拌ΙΊ、化之情形。另一方面,本發明i至5之產品顯示其 於室溫存放12個月後濃稠度之升高被抑制、有好的攪拌性 及延展性、且非常容易使用。 此外,树明之緯白糖(以肌c測量)及碟之有 滴定法測量)經存化於室溫12個月後依然穩定。"
O:\89\89230.DOC -14·
Claims (1)
- 200418496 拾、申請專利範園: 1· 一種皮膚損傷修復發合#,其含有50至9()重量%之酷 類、0.5至10重量。/。之普咸隆碘、〇1至2〇重量%之水、及 0.01至10重量%之磷脂。 2 · 如申請專利範圍第1項之由 皮膚損傷修復用組合物,其中該 醣類為綿白糖。 3·如申a月專利範圍第1或2項之皮膚損傷修復用組合物,其 中該磷脂為天然磷脂或氫化磷脂。 4·如申請專利範圍第1或2項之皮膚損傷修復用組合物,其 pH為 3.5至 6。 O:\89\89230.DOC 200418496 柒、指定代表圖: (一) 本案指定代表圖為:(無)。 (二) 本代表圖之元件代表符號簡單說明: 捌、本案若有化學式時,請揭示最能顯示發明特徵的化學式: (無) O:\89\89230.DOC
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002326535 | 2002-11-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200418496A true TW200418496A (en) | 2004-10-01 |
Family
ID=32310502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW092131556A TW200418496A (en) | 2002-11-11 | 2003-11-11 | A composition for repairing injured skin |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20060034945A1 (zh) |
| EP (1) | EP1561467A4 (zh) |
| JP (1) | JP4391948B2 (zh) |
| KR (1) | KR101056410B1 (zh) |
| CN (1) | CN1711095B (zh) |
| AU (1) | AU2003277640A1 (zh) |
| TW (1) | TW200418496A (zh) |
| WO (1) | WO2004043473A1 (zh) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005045760B4 (de) | 2005-09-23 | 2008-12-24 | Hoffmann Consorten Hamburg Gmbh | Verfahren und Vorrichtung zur Herstellung einer konditionierten Atmosphäre |
| CN102125053B (zh) * | 2011-01-07 | 2013-08-07 | 上海宇昂水性新材料科技股份有限公司 | 高稳定非离子n-乙烯基丁内酰胺碘溶液及相关配制方法 |
| CN106265479A (zh) * | 2016-10-27 | 2017-01-04 | 广州仙施生物科技有限公司 | 一种皮肤修复组合物及其制备方法 |
| JP6997222B2 (ja) | 2017-06-23 | 2022-01-17 | ザ プロクター アンド ギャンブル カンパニー | 皮膚の外観を改善するための組成物及び方法 |
| WO2019079661A1 (en) * | 2017-10-20 | 2019-04-25 | Georgetown University | COMPOSITION CONTAINING SILK FIBROIN AND METHODS OF USE |
| EP3817717A1 (en) | 2018-07-03 | 2021-05-12 | The Procter & Gamble Company | Method of treating a skin condition |
| US10959933B1 (en) | 2020-06-01 | 2021-03-30 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
| JP7590462B2 (ja) | 2020-06-01 | 2024-11-26 | ザ プロクター アンド ギャンブル カンパニー | ビタミンb3化合物の皮膚への浸透を改善する方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4401651A (en) * | 1979-04-18 | 1983-08-30 | Knutson Richard A | Wound-healing compositions containing povidone-iodine |
| US4323365A (en) * | 1980-07-24 | 1982-04-06 | Occidental Research Corporation | Dewatering of solid residues of carbonaceous materials |
| JPS61251605A (ja) * | 1985-04-30 | 1986-11-08 | Shiseido Co Ltd | 化粧料 |
| JPH0692310B2 (ja) * | 1987-03-04 | 1994-11-16 | 新技術事業団 | 創傷治療剤 |
| US5025004A (en) * | 1988-06-13 | 1991-06-18 | Eastman Kodak Company | Water-dispersible polymeric compositions |
| DE9312509U1 (de) * | 1993-08-20 | 1993-10-28 | Euro-Celtique S.A., Luxemburg/Luxembourg | Präparate zur äußeren Verabreichung von antiseptischen und/oder die Wundheilung fördernden Wirkstoffen |
| JP3583166B2 (ja) * | 1994-06-27 | 2004-10-27 | 興和株式会社 | 損傷皮膚修復用粉末製剤 |
| JP3825510B2 (ja) * | 1996-10-07 | 2006-09-27 | 三菱化学株式会社 | 蔗糖脂肪酸エステル水溶液の粘度低下剤 |
| JP2000038342A (ja) * | 1998-05-18 | 2000-02-08 | Kyowa Yakuhin Kogyo Kk | 褥瘡・損傷皮膚修復用製剤 |
| DE29923766U1 (de) * | 1998-05-27 | 2001-06-07 | Euroceltique S.A., Luxemburg/Luxembourg | Wirkstoffapplikationssystem umfassend einen hochverdichteten festen Arzneimittelvorrat |
| JP2000066457A (ja) * | 1998-08-20 | 2000-03-03 | Minolta Co Ltd | 液体現像方法、濃縮液体現像剤及び希釈液並びに希釈液の製造方法 |
| US6756368B1 (en) * | 1999-07-16 | 2004-06-29 | The Trustees Of Columbia University In The City Of New York | Use of cobalt chelates for treating or preventing virus infection |
| US6509301B1 (en) * | 1999-08-26 | 2003-01-21 | Daniel Patrick Vollmer | Well treatment fluids and methods for the use thereof |
| JP2001122790A (ja) * | 1999-10-22 | 2001-05-08 | Mikasa Seiyaku Co Ltd | 安定な褥瘡・皮膚潰瘍および創傷治療用製剤 |
| JP4841733B2 (ja) | 2001-01-31 | 2011-12-21 | 三笠製薬株式会社 | 創傷治療用製剤 |
-
2003
- 2003-11-10 KR KR1020057007198A patent/KR101056410B1/ko not_active Expired - Lifetime
- 2003-11-10 JP JP2004551209A patent/JP4391948B2/ja not_active Expired - Fee Related
- 2003-11-10 WO PCT/JP2003/014251 patent/WO2004043473A1/ja not_active Ceased
- 2003-11-10 AU AU2003277640A patent/AU2003277640A1/en not_active Abandoned
- 2003-11-10 EP EP03811090A patent/EP1561467A4/en not_active Withdrawn
- 2003-11-10 CN CN2003801029261A patent/CN1711095B/zh not_active Expired - Fee Related
- 2003-11-10 US US10/533,659 patent/US20060034945A1/en not_active Abandoned
- 2003-11-11 TW TW092131556A patent/TW200418496A/zh unknown
-
2009
- 2009-08-25 US US12/583,729 patent/US20090317354A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004043473A1 (ja) | 2004-05-27 |
| EP1561467A1 (en) | 2005-08-10 |
| KR20050083831A (ko) | 2005-08-26 |
| US20090317354A1 (en) | 2009-12-24 |
| US20060034945A1 (en) | 2006-02-16 |
| JPWO2004043473A1 (ja) | 2006-03-09 |
| KR101056410B1 (ko) | 2011-08-11 |
| EP1561467A4 (en) | 2008-06-25 |
| JP4391948B2 (ja) | 2009-12-24 |
| AU2003277640A8 (en) | 2004-06-03 |
| CN1711095B (zh) | 2011-09-21 |
| CN1711095A (zh) | 2005-12-21 |
| AU2003277640A1 (en) | 2004-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101792200B1 (ko) | 열감응성 겔 마취제 조성물 | |
| EP2729131B1 (en) | Topical compositions | |
| TWI642439B (zh) | 對於防止黏連或止血有用之醫藥組成物 | |
| US20090317354A1 (en) | Composition for restoring damaged skin comprising a saccaride and povidone-iodine | |
| FI69753C (fi) | Foerfarande foer framstaellning av en salva pao basis av isosorbiddinitrat | |
| EA004683B1 (ru) | Фармацевтическая композиция, содержащая омепразол | |
| EP3006056A1 (en) | Adhesion preventing material | |
| RU2261088C2 (ru) | Фосфолипидный гель | |
| KR20080032597A (ko) | 사람 피부에 적용 가능하고, 물과의 접촉시 겔화될 수 있는고체 화장용 및 치료학적 조성물 | |
| US9925266B2 (en) | Gelling formulation based on calcium gluconate | |
| JP3472442B2 (ja) | 損傷皮膚修復用製剤 | |
| JP2006117539A (ja) | 油性軟膏剤 | |
| CA2685862C (en) | Stabilized formulation of triamcinolone acetonide | |
| JP4494202B2 (ja) | インドメタシン外用剤 | |
| Taguchi et al. | Evaluation of tumor tissue fixation effects of formulation modified Mohs pastes in mice and their water-absorbing properties | |
| JP4559111B2 (ja) | 損傷皮膚修復用組成物 | |
| JP5301205B2 (ja) | ゲル軟膏組成物 | |
| JP2012517995A (ja) | フシジン酸ナトリウムを用いて作製した皮膚用医薬品ゲルおよびその作製方法 | |
| JP4575705B2 (ja) | 損傷皮膚修復用組成物 | |
| JP4463337B2 (ja) | 軟膏製剤 | |
| HK1082678A (zh) | 损伤皮肤修复用组合物 | |
| JP2002241287A (ja) | 皮膚潰瘍治療用組成物 | |
| JPH11506441A (ja) | ソルビン酸含有ヒドロゲル | |
| JP2008105986A (ja) | インドメタシン外用ゲル剤 | |
| JPH0311014A (ja) | 外用ゲル製剤 |